



State of Oklahoma
 SoonerCare
 Margenza® (Margetuximab-cmkb)
 Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician billing (HCPCS code: _____) Pharmacy billing (NDC: _____)

Dose: _____ Regimen: _____ Start Date (or date of next dose): _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria

For Initial Authorization

1. Please indicate the diagnosis and information:

Breast Cancer

- A. Is disease metastatic? Yes ___ No ___
- B. Is disease human epidermal receptor type 2 (HER2)-positive? Yes ___ No ___
- C. Has member received 2 or more prior anti-HER2 regimens with at least 1 treatment for metastatic disease? Yes ___ No ___
- D. Will margetuximab-cmkb be used in combination with chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)? Yes ___ No ___

If answer is none of the above, please indicate diagnosis: _____

Additional Information: _____

For Continued Authorization:

- 1. Date of last dose: _____
- 2. Does member have any evidence of progressive disease while on margetuximab-cmkb ?
Yes ___ No ___
- 3. Has the member experienced adverse drug reactions related to margetuximab-cmkb therapy?
Yes ___ No ___

If yes, please specify adverse reactions: _____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
 Pharmacy Management Consultants
 Product Based Prior Authorization Unit

Fax: 1-800-224-4014
 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.